So-Young Reports Unaudited Third Quarter 2024 Financial Results

Rhea-AI Summary

So-Young International reported Q3 2024 financial results with total revenues of RMB371.8 million (US$53.0 million), down 3.5% year-over-year but exceeding guidance. Net income rose to RMB20.3 million (US$2.9 million), up from RMB18.3 million in Q3 2023. Sales of medical products grew 18.7% year-over-year, while information services revenue declined 8.0%. The company expanded its clinic network to 16 stores and improved operational efficiency, resulting in an 8.1% decrease in operating expenses. For Q4 2024, So-Young expects revenues between RMB350.0-370.0 million, representing a 5.3-10.4% year-over-year decrease.

Positive

• Net income increased 8.9% YoY to RMB20.3 million
• Medical products sales grew 18.7% YoY to RMB89.3 million
• Operating expenses decreased 8.1% to RMB225.0 million
• Non-GAAP net income grew 133.1% YoY to RMB22.2 million
• Clinic network expanded to 16 stores in major cities

Negative

• Total revenues declined 3.5% YoY to RMB371.8 million
• Information services revenue decreased 8.0% YoY
• Mobile MAUs dropped to 1.4 million from 3.1 million YoY
• Number of subscribing medical service providers decreased to 1,322 from 1,397
• Q4 2024 guidance projects 5.3-10.4% revenue decline YoY

Insights

Financial Analyst

So-Young's Q3 results present a mixed picture. While total revenues declined 3.5% YoY to RMB371.8 million, the company exceeded guidance and showed improved profitability. The standout performer was medical products and maintenance services, growing 18.7% YoY to RMB89.3 million.

Key concerns include declining user metrics, with mobile MAUs dropping significantly from 3.1M to 1.4M YoY. However, cost management initiatives are yielding results - operating expenses decreased 8.1% YoY, leading to improved margins. The non-GAAP net income showed impressive growth of 133.1% YoY.

The Q4 guidance suggesting a 5.3-10.4% revenue decline indicates continued near-term challenges in the core business, though the company's expansion to 16 physical stores and focus on product sales could help offset these headwinds.

Market Research Analyst

The company's strategic pivot toward physical retail and product sales demonstrates adaptation to market challenges. The expansion to 16 stores in prime locations, coupled with plans for franchising, signals a significant business model evolution from a pure digital platform to an omnichannel player.

The declining information services revenue (-8.0% YoY) and reservation services (-18.9% YoY) reflect broader challenges in China's medical aesthetics market. However, the 18.7% growth in product sales suggests successful vertical integration and diversification efforts.

The strong cash position of RMB1,252.6 million provides ample runway for executing the retail expansion strategy, though investors should monitor the pace of cash burn as the company scales its physical presence.

BEIJING, Nov. 20, 2024 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced its unaudited financial results for the third quarter ended September 30, 2024.

Third Quarter 2024 Financial Highlights

• Total revenues were RMB371.8 million (US$53.0 million^[1]), compared with RMB385.3 million in the corresponding period of 2023, exceeding the high end of guidance.
• Net income attributable to So-Young International Inc. was RMB20.3 million (US$2.9 million), compared with net income attributable to So-Young International Inc. of RMB18.3 million in the same period of 2023.
• Non-GAAP net income attributable to So-Young International Inc.^[2] was RMB22.2 million (US$3.2 million), compared with non-GAAP net income attributable to So-Young International Inc. of RMB9.5 million in the same period of 2023.

Third Quarter 2024 Operational Highlights

• Average mobile MAUs were 1.4 million, compared with 3.1 million in the third quarter of 2023.
• Number of medical service providers subscribing to information services on So-Young's platform was 1,322, compared with 1,397 in the third quarter of 2023.
• Total number of purchasing users through reservation services was 114.9 thousand and the aggregate value of medical aesthetic treatment transactions facilitated by So-Young's platform was RMB346.0 million.

Mr. Xing Jin, Co-Founder and Chief Executive Officer of So-Young, said, "Our third quarter performance beat the high end of our guidance once again, highlighting the resilience of our business. Sales of medical products and maintenance services grew by 18.7% year-over-year, becoming a key growth driver contributing to a year-over-year increase in net income. This underscores the effectiveness of our strategy to stay at the forefront of industry trends by deepening the synergies from our vertical integration and continuously diversifying our offerings. Our clinic network has experienced significant growth. The number of stores has grown to 16 by the end of this quarter, extending our presence into additional major cities. All stores are situated in central business districts, enhancing our market coverage and competitive position. To further scale our offline presence, we are accelerating the deployment of this proven standardized model in other cities nationwide and are exploring franchising opportunities to engage with a wider audience. The reputational strength of our brand and our deep understanding of evolving consumer behavior uniquely position us to develop products that resonate with consumer needs. Sales momentum remains robust, driven by both our well-established products and exciting new launches in collaboration with our supply chain partners. Looking ahead, we are committed to seizing opportunities across the entire medical aesthetics value chain while deepening the integration of our three core businesses to maximize operational efficiency, customer satisfaction, and sustainable growth."

Mr. Hui Zhao, Chief Financial Officer of So-Young, added, "Our third-quarter results reflect our ability to strategically adapt to changing market dynamics. Through disciplined cost management and targeted growth initiatives, we are carefully navigating this challenging market environment while building a solid foundation for future expansion. Encouragingly, our net income and non-GAAP net income attributable to So-Young International Inc. improved significantly, with year-over-year growth rates exceeding 8.9% and 133.1% respectively. Looking ahead, we will leverage our expanding network of clinics and meticulously curated product offerings to address the growing demand for high-quality solutions and services. By maintaining operational efficiency and scalability, we are well-positioned to continue leading the medical aesthetics sector, delivering sustainable growth and long-term value for our shareholders."

[1] This press release contains translations of certain Renminbi (RMB) amounts into U.S. dollars (US$) solely for the convenience of the reader. Unless otherwise specified, all translations of Renminbi amounts into U.S. dollar amounts in this press release are made at RMB7.0176 to US$1.00, which was the U.S. dollars middle rate announced by the Board of Governors of the Federal Reserve System of the United States on September 30, 2024.

[2] Non-GAAP net income attributable to So-Young International Inc. is defined as net income attributable to So-Young International Inc. excluding share-based compensation expenses attributable to So-Young International Inc. See "Reconciliation of GAAP and Non-GAAP Results" at the end of this press release.

Third Quarter 2024 Financial Results     

Revenues

Total revenues were RMB371.8 million (US$53.0 million), a decrease of 3.5% from RMB385.3 million in the same period of 2023. The decrease was primarily due to a decrease in the number of medical service providers subscribing to information services on So-Young's platform.

• Information services and other revenues were RMB263.0 million (US$37.5 million), a decrease of 8.0% from RMB285.9 million in the same period of 2023. The decrease was primarily due to a decrease in the number of medical service providers subscribing to information services on So-Young's platform.
• Reservation services revenues were RMB19.6 million (US$2.8 million), a decrease of 18.9% from RMB24.1 million in the same period of 2023. The decrease was primarily due to a decrease in consumer spending through our platform.
• Sales of medical products and maintenance services were RMB89.3 million (US$12.7 million), an increase of 18.7% from RMB75.2 million in the same period of 2023, primarily due to an increase in the order volumes for cosmetic products and medical equipment.

Cost of Revenues

Cost of revenues was RMB142.2 million (US$20.3 million), a decrease of 0.3% from RMB142.6 million in the third quarter of 2023. The decrease was primarily due to a decrease in the cost of services associated with the information services. Cost of revenues included share-based compensation expenses of RMB0.1 million (US$0.0 million), compared with the share-based compensation expenses of RMB0.4 million in the corresponding period of 2023.

• Cost of services and others were RMB98.6 million (US$14.1 million), a decrease of 4.7% from RMB103.5 million in the third quarter of 2023. The decrease was primarily due to a decrease in the cost of services associated with the information services.
• Cost of medical products sold and maintenance services were RMB43.5 million (US$6.2 million), an increase of 11.3% from RMB39.1 million in the third quarter of 2023. The increase was primarily due to an increase in costs associated with the sales of cosmetic products.

Operating Expenses

Total operating expenses were RMB225.0 million (US$32.1 million), a decrease of 8.1% from RMB244.7 million in the third quarter of 2023.

• Sales and marketing expenses were RMB114.9 million (US$16.4 million), a decrease of 20.1% from RMB143.8 million in the third quarter of 2023. The decrease was mainly due to a decrease in expenses associated with branding and user acquisition activities. Sales and marketing expenses included share-based compensation expenses of RMB0.2 million (US$0.0 million), compared with RMB0.5 million in the corresponding period of 2023.
• General and administrative expenses were RMB69.9 million (US$10.0 million), an increase of 39.1% from RMB50.2 million in the third quarter of 2023. The increase was primarily due to an increase in share-based compensation expenses. General and administrative expenses included share-based compensation expenses of RMB1.3 million (US$0.2 million), compared with a reversal of share-based compensation expenses of RMB11.2 million in the corresponding period of 2023.
• Research and development expenses were RMB40.2 million (US$5.7 million), a decrease of 20.6% from RMB50.6 million in the third quarter of 2023. The decrease was primarily attributable to improvements in staff efficiency. Research and development expenses included share-based compensation expenses of RMB0.3 million (US$0.0 million), compared with RMB1.5 million in the corresponding period of 2023.

Income Tax (Expenses)/Benefits

Income tax expenses were RMB2.1 million (US$0.3 million), compared with income tax benefits of RMB2.2 million in the same period of 2023.

Net Income Attributable to So-Young International Inc.

Net income attributable to So-Young International Inc. was RMB20.3 million (US$2.9 million), compared with a net income attributable to So-Young International Inc. of RMB18.3 million in the third quarter of 2023.

Non-GAAP Net Income Attributable to So-Young International Inc.

Non-GAAP net income attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses attributable to So-Young International Inc., was RMB22.2 million (US$3.2 million), compared with RMB9.5 million non-GAAP net income attributable to So-Young International Inc. in the same period of 2023.

Basic and Diluted Earnings per ADS

Basic and diluted earnings per ADS attributable to ordinary shareholders were RMB0.20 (US$0.03) and RMB0.20 (US$0.03), respectively, compared with basic and diluted earnings per ADS attributable to ordinary shareholders of RMB0.18 and RMB0.18, respectively, in the same period of 2023.

Cash and Cash Equivalents, Restricted Cash and Term Deposits, Term Deposits and Short-Term Investments

As of September 30, 2024, cash and cash equivalents, restricted cash and term deposits, term deposits and short-term investments were RMB1,252.6 million (US$178.5 million), compared with RMB1,341.6 million as of December 31, 2023.

Business Outlook

For the fourth quarter of 2024, So-Young expects total revenues to be between RMB350.0 million (US$49.9 million) and RMB370.0 million (US$52.7 million), representing a 10.4% to 5.3% decrease from the same period in 2023. The above outlook is based on the current market conditions and reflects the Company's preliminary estimates of market and operating conditions, as well as customer demand, which are all subject to change.

Non-GAAP Financial Measures

To supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States, or GAAP, this press release presents non-GAAP income/(loss) from operations and non-GAAP net income attributable to So-Young International Inc. by excluding share-based compensation expenses from income/(loss) from operations and net income attributable to So-Young International Inc., respectively. The Company believes these non-GAAP financial measures are important to help investors understand the Company's operating and financial performance, compare business trends among different reporting periods on a consistent basis and assess the Company's core operating results, as they exclude certain expenses that are not expected to result in cash payments. The use of the above non-GAAP financial measures has certain limitations. Share-based compensation expenses have been and will continue to be incurred in the future. All these are not reflected in the presentation of the non-GAAP financial measures, but should be considered in the overall evaluation of the Company's results. The Company compensates for these limitations by providing the relevant disclosure of its share-based compensation expenses in the reconciliations to the most directly comparable GAAP financial measures, which should be considered when evaluating the Company's performance. These non-GAAP financial measures should be considered in addition to financial measures prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP. Reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measure is set forth at the end of this release.

Conference Call Information

So-Young's management will hold an earnings conference call on Wednesday, November 20, 2024, at 7:00 AM U.S. Eastern Time (8:00 PM on the same day, Beijing/Hong Kong Time). Dial-in details for the earnings conference call are as follows:

International:	+1-412-902-4272
Mainland China:	4001-201203
US:	+1-888-346-8982
Hong Kong:	+852-301-84992
Passcode:	So-Young International Inc.

A telephone replay will be available two hours after the conclusion of the conference call through 23:59 U.S. Eastern Time, November 27, 2024. The dial-in details are:

International:	+1-412-317-0088
US:	+1-877-344-7529
Passcode:	2642052

Additionally, a live and archived webcast of this conference call will be available at http://ir.soyoung.com.

About So-Young International Inc.

So-Young International Inc. (Nasdaq: SY) is the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry. The Company presents users with reliable information through offering high quality and trustworthy content together with a multitude of social functions on its platform, as well as by curating medical aesthetic service providers that are carefully selected and vetted. Leveraging So-Young's strong brand image, extensive audience reach, trust from its users, highly engaging social community and data insights, the Company is well-positioned to expand both along the medical aesthetic industry value chain and into the massive, fast-growing consumption healthcare service market.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, the Financial Guidance and quotations from management in this announcement, as well as So-Young's strategic and operational plans, contain forward-looking statements. So-Young may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about So-Young's beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: So-Young's strategies; So-Young's future business development, financial condition and results of operations; So-Young's ability to retain and increase the number of users and medical service providers, and expand its service offerings; competition in the online medical aesthetic service industry; changes in So-Young's revenues, costs or expenditures; Chinese governmental policies and regulations relating to the online medical aesthetic service industry, general economic and business conditions globally and in China; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company's filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and So-Young undertakes no duty to update such information, except as required under applicable law.

For more information, please contact:

So-Young

Investor Relations
Ms. Mona Qiao
Phone: +86-10-8790-2012
E-mail: ir@soyoung.com 

Christensen

In China
Ms. Dee Wang
Phone: +86-10-5900-1548
E-mail: dee.wang@christensencomms.com 

In US
Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email: linda.bergkamp@christensencomms.com 

SO-YOUNG INTERNATIONAL INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except for share and per share data)
	As of
	December 31,		September 30,		September 30,
	2023		2024		2024
	RMB		RMB		US$
Assets
Current assets:
Cash and cash equivalents	426,119		467,407		66,605
Restricted cash and term deposits	14,695		104,198		14,848
Trade receivables	57,219		106,943		15,239
Inventories	118,924		145,601		20,748
Receivables from online payment platforms	23,158		31,666		4,512
Amounts due from related parties	9,212		10,466		1,491
Term deposits and short-term investments	900,823		681,035		97,047
Prepayment and other current assets	171,774		221,227		31,525
Total current assets	1,721,924		1,768,543		252,015
Non-current assets:
Long-term investments	261,016		287,507		40,969
Intangible assets	145,253		131,641		18,759
Goodwill	540,693		540,693		77,048
Property and equipment, net	116,782		154,572		22,026
Deferred tax assets	78,034		81,057		11,551
Operating lease right-of-use assets	118,408		159,179		22,683
Other non-current assets	232,455		180,628		25,739
Total non-current assets	1,492,641		1,535,277		218,775
Total assets	3,214,565		3,303,820		470,790
Liabilities
Current liabilities:
Short-term borrowings	29,825		89,559		12,762
Taxes payable	56,894		53,639		7,643
Contract liabilities	103,374		94,747		13,501
Salary and welfare payables	86,290		84,927		12,102
Amounts due to related parties	388		146		21
Accrued expenses and other current liabilities	233,913		244,721		34,873
Operating lease liabilities-current	29,739		40,398		5,757
Total current liabilities	540,423		608,137		86,659
Non-current liabilities:
Operating lease liabilities-non current	86,210		124,915		17,800
Deferred tax liabilities	25,082		20,780		2,961
Other non-current liabilities	1,536		1,607		229
Total non-current liabilities	112,828		147,302		20,990
Total liabilities	653,251		755,439		107,649
SO-YOUNG INTERNATIONAL INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Continued)
(Amounts in thousands, except for share and per share data)
Shareholders' equity:
Treasury stock	(358,453)		(369,907)		(52,711)
Class A ordinary shares (US$0.0005 par value; 750,000,000      shares authorized as of December 31, 2023 and September      30, 2024; 73,688,044 and 63,422,436 shares issued and      outstanding as of December 31, 2023, 77,634,580 and      66,170,882 shares issued and outstanding as of September      30, 2024, respectively)	238		252		36
Class B ordinary shares (US$ 0.0005 par value; 20,000,000      shares authorized as of December 31, 2023 and September      30, 2024; 12,000,000 shares issued and outstanding as of      December 31, 2023 and September 30, 2024)	37		37		5
Additional paid-in capital	3,080,433		3,067,567		437,125
Statutory reserves	33,855		33,855		4,824
Accumulated deficit	(330,166)		(312,117)		(44,476)
Accumulated other comprehensive income	18,185		8,858		1,262
Total So-Young International Inc. shareholders' equity	2,444,129		2,428,545		346,065
Non-controlling interests	117,185		119,836		17,076
Total shareholders' equity	2,561,314		2,548,381		363,141
Total liabilities and shareholders' equity	3,214,565		3,303,820		470,790

 

SO-YOUNG INTERNATIONAL INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands, except for share and per share data)
	For the Three Months Ended						For the Nine Months Ended
	September  30, 2023		September 30, 2024		September 30, 2024		September 30, 2023		September 30, 2024		September 30, 2024
	RMB		RMB		US$		RMB		RMB		US$
Revenues:
Information services and others	285,937		262,988		37,475		795,100		750,952		107,010
Reservation services	24,140		19,567		2,788		80,724		64,987		9,261
Sales of medical products and maintenance services	75,217		89,270		12,721		231,639		281,548		40,120
Total revenues	385,294		371,825		52,984		1,107,463		1,097,487		156,391
Cost of revenues:
Cost of services and others	(103,484)		(98,620)		(14,053)		(291,503)		(274,695)		(39,144)
Cost of medical products sold and maintenance services	(39,119)		(43,548)		(6,206)		(115,199)		(139,839)		(19,927)
Total cost of revenues	(142,603)		(142,168)		(20,259)		(406,702)		(414,534)		(59,071)
Gross profit	242,691		229,657		32,725		700,761		682,953		97,320
Operating expenses:
Sales and marketing expenses	(143,844)		(114,884)		(16,371)		(394,276)		(360,448)		(51,363)
General and administrative expenses	(50,242)		(69,901)		(9,961)		(204,097)		(225,653)		(32,155)
Research and development expenses	(50,597)		(40,188)		(5,727)		(158,531)		(122,277)		(17,424)
Total operating expenses	(244,683)		(224,973)		(32,059)		(756,904)		(708,378)		(100,942)
(Loss)/Income from operations	(1,992)		4,684		666		(56,143)		(25,425)		(3,622)
Other income/(expenses):
Investment income, net	647		510		73		10,869		3,397		484
Interest income, net	12,130		14,239		2,029		38,023		38,270		5,453
Exchange gains/(losses)	103		465		66		(1,051)		875		125
Share of losses of equity method investee	(3,822)		(3,873)		(552)		(10,692)		(11,602)		(1,653)
Others, net	9,887		6,915		985		18,474		12,234		1,743
Income/(Loss) before tax	16,953		22,940		3,267		(520)		17,749		2,530
Income tax benefits/(expenses)	2,191		(2,097)		(299)		7,240		3,031		432
Net income	19,144		20,843		2,968		6,720		20,780		2,962
Net income attributable to noncontrolling interests	(839)		(495)		(71)		(2,941)		(2,731)		(389)
Net income attributable to So-Young International Inc.	18,305		20,348		2,897		3,779		18,049		2,573

 

SO-YOUNG INTERNATIONAL INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Continued)
(Amounts in thousands, except for share and per share data)
	For the Three Months Ended						For the Nine Months Ended
	September 30, 2023		September 30, 2024		September 30, 2024		September 30, 2023		September 30, 2024		September 30, 2024
	RMB		RMB		US$		RMB		RMB		US$
Net earnings per ordinary share
Net earnings per ordinary share attributable to ordinary shareholder - basic	0.24		0.26		0.04		0.05		0.23		0.03
Net earnings per ordinary share attributable to ordinary shareholder - diluted	0.24		0.26		0.04		0.05		0.23		0.03
Net earnings per ADS attributable to ordinary shareholders - basic (13 ADS      represents 10 Class A ordinary shares)	0.18		0.20		0.03		0.04		0.18		0.03
Net earnings per ADS attributable to ordinary shareholders - diluted (13 ADS      represents 10 Class A ordinary shares)	0.18		0.20		0.03		0.04		0.18		0.03
Weighted average number of ordinary shares used in computing earnings/(loss)      per share, basic*	76,842,709		79,493,819		79,493,819		78,001,149		79,544,066		79,544,066
Weighted average number of ordinary shares used in computing earnings/(loss)      per share, diluted*	77,210,781		79,708,518		79,708,518		78,402,636		79,810,666		79,810,666
Share-based compensation expenses included in:
Cost of services and others	(418)		(81)		(12)		(1,635)		(255)		(36)
Sales and marketing expenses	(533)		(183)		(26)		(2,850)		(420)		(60)
General and administrative expenses	11,164		(1,328)		(189)		(10,400)		(27,796)		(3,961)
Research and development expenses	(1,454)		(309)		(44)		(3,636)		(1,969)		(281)
* Both Class A and Class B ordinary shares are included in the calculation of the weighted average number of ordinary shares outstanding, basic and diluted.

 

SO-YOUNG INTERNATIONAL INC.
Reconciliation of GAAP and Non-GAAP Results
(Amounts in thousands, except for share and per share data)
	For the Three Months Ended						For the Nine Months Ended
	September 30, 2023		September  30, 2024		September 30, 2024		September 30, 2023		September 30, 2024		September 30, 2024
	RMB		RMB		US$		RMB		RMB		US$
GAAP (loss)/income from operations	(1,992)		4,684		666		(56,143)		(25,425)		(3,622)
Add back: Share-based compensation expenses	(8,759)		1,901		271		18,521		30,440		4,338
Non-GAAP (loss)/income from operations	(10,751)		6,585		937		(37,622)		5,015		716
GAAP net income attributable to So-Young International Inc.	18,305		20,348		2,897		3,779		18,049		2,573
Add back: Share-based compensation expenses	(8,759)		1,901		271		18,521		30,440		4,338
Non-GAAP net income attributable to So-Young International Inc.	9,546		22,249		3,168		22,300		48,489		6,911

 

 

View original content:https://www.prnewswire.com/news-releases/so-young-reports-unaudited-third-quarter-2024-financial-results-302311180.html

SOURCE So-Young International Inc.

FAQ

What was So-Young's (SY) revenue in Q3 2024?

So-Young (SY) reported total revenues of RMB371.8 million (US$53.0 million) in Q3 2024, representing a 3.5% decrease from RMB385.3 million in Q3 2023.

How much did So-Young's (SY) medical products sales grow in Q3 2024?

So-Young's (SY) sales of medical products and maintenance services grew 18.7% year-over-year to RMB89.3 million in Q3 2024.

What is So-Young's (SY) revenue guidance for Q4 2024?

So-Young (SY) expects Q4 2024 total revenues to be between RMB350.0 million and RMB370.0 million, representing a 10.4% to 5.3% decrease year-over-year.

How many clinics does So-Young (SY) operate as of Q3 2024?

So-Young (SY) operated 16 clinics in major cities' central business districts as of Q3 2024.